At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 518 enrolled
Drug / intervention
LEVI-04 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee
In Brief
A Phase 2 clinical trial evaluating LEVI-04 and Placebo for Pain and 6 related conditions. Completed, enrolled 518 participants across 13 sites in 5 countries.
Detailed Summary
This is a phase 2, randomized, double-blind, placebo-controlled trial of multiple doses and multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Osteo Arthritis Knee, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
CountriesCzechia, Denmark, Hong Kong, Moldova, Poland
CollaboratorsNordic Bioscience Clinical Development (NBCD)
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartOct 2022
First PostedNov 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedNov 16, 2022
Enrollment StartOct 19, 2022
Primary CompletionMay 20, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.6 years ago
Interventions
LEVI-04drug
LEVI-04, a fully human chimeric fusion protein that combines the Fc fragment of human immunoglobulin G1 with the p75 neurotrophin receptor (p75 NTR), for the treatment of chronic pain.
Placeboother
Saline vehicle